The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.
Familial hibernian fever Multiple sclerosis 5
Contains 1 death domain. Contains 4 TNFR-Cys repeats.
The domain that induces A-SMASE is probably identical to the death domain. The N-SMASE activation domain (NSD) is both necessary and sufficient for activation of N-SMASE. Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in the interaction with TRPC4AP.
The soluble form is produced from the membrane form by proteolytic processing.
Cell membrane. Golgi apparatus membrane. Secreted. A secreted form is produced through proteolytic processing and Secreted. Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.
Tumor necrosis factor receptor superfamily, member 1A antibody
Tumor necrosis factor receptor type 1 antibody
Tumor necrosis factor receptor type I antibody
Tumor necrosis factor-binding protein 1 antibody
Immunohistochemistry (Paraffin-embedded sections) - TNF Receptor I antibody (ab58436)
ab58436, at 1/50 dilution, staining TNF Receptor I in paraffin embedded human breast carcinoma tissue by Immunohistochemistry in the absence (left image) or presence (right image) of the immunising peptide.
Shivakumar P et al. Preferential TNFa signaling via TNFR2 regulates epithelial injury and duct obstruction in experimental biliary atresia. JCI Insight2:e88747 (2017).
Read more (PubMed: 28289704) »
Moutsopoulos NM et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis67:1437-43 (2008).
Read more (PubMed: 18198195) »